Drug
ATYR1923 (Efzofitimod)
Status:
Phase 3
Condition:
Sarcoidosis ILD
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Industry
Drug Details
Efzofitimod (ATYR1923) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of histidyl-tRNA synthetase (HARS). Efzofitimod selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis.
Study Purpose
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.